Objectives-To investigate the incidence of allergy to laboratory animals (ALA) during the first two years of employment, and to study the effect on ALA of atopy and sensitisation. Methods-A follow up prospective study of ALA at the Zeneca (formerly ICI) Research Laboratories. Results-The incidence of the disease during the first year of employment has remained at about 10% since the mid1980s. This compares with an incidence of 37% in the early 1980s. The reduction in incidence and its maintenance at a lower level is thought to be due to the introduction and management of improved engineering controls, working practices, and educational programmes designed to reduce exposure to allergens from laboratory animals. The underlying incidence of immunological sensitisation to animals ( Two of these prospective studies also investigated the influence of one or more atopic indicators on the development of ALA.26 In both of these studies, it was concluded that the exclusion of people with atopy from working with animals could not be justified, as for every case of ALA that would theoretically be prevented, at least three people who would never develop the problem would also be denied employment.At ICI (now Zeneca), since the mid-1980s there has been a coordinated process to try to maintain or reduce further the incidence of ALA by means of improved engineering controls and the use of personal protective equipment as well as by health surveillance and educational programmes. We report one outcome of this, namely the incidence of ALA during the first two years of employment in a group of 200 scientists and technicians recruited by ICI since the last study (from 1987-1990). The paper also considers the influence of atopy and of pre-existing sensitisation to laboratory animals on the development of ALA.
ObjectiveInflammatory bowel disease (IBD) is increasingly managed with the use of biologic therapies. National guidelines (National Institute for Health and Care Excellence (NICE)) suggest considering cessation after 1 year of therapy but lack detailed criteria for this. We aimed to describe clinical outcomes from the introduction of a biologic review panel (BRP) to implement modified criteria for cessation of antitumour necrosis factor (anti-TNF) therapy and step down to single-agent immunomodulator.DesignRetrospective review of patient outcomes following BRP implementation.PatientsAll patients on biologic therapy discussed in the BRP within a 5-year period.SettingSingle IBD network covering three hospital sites.InterventionsModified criteria for biologic cessation were based on published evidence; they excluded individuals with no suitable maintenance immunomodulator, previous surgery or evidence of active disease, additional indications for anti-TNF therapy and previous relapse on biologic cessation. All patients with IBD on a biologic were discussed at the BRP.Main outcome measuresRelapse following IBD cessation and relative cost of BRP.Results136 patients with IBD were reviewed, with 45 patients meeting the NICE guideline criteria for cessation. The BRP and modified criteria affected decision to withdraw therapy in 38% of these. Therapy was withdrawn in 27 patients, with a 20% 24-month relapse rate. Younger age at cessation was significantly associated with relapse (p=0.01).ConclusionThe BRP approach has proved a safe and effective means of decision making in stopping biologic therapy. Future work to inform exclusion criteria is required.
Background: Vedolizumab is an anti-α4β7 integrin that is indicated for use in moderate-to-severe ulcerative colitis and Crohn's disease. There is limited study into its safety and efficacy in pregnancy. We present two case reports, each with a successful pregnancy with vedolizumab-treated inflammatory bowel disease (IBD). Methods: Retrospective and observational study of two pregnant women with IBD who were treated with vedolizumab throughout pregnancy. Clinical information on both patients was collected from reading through electronically scanned patient notes and clinic letters. Information collected included: time and age of diagnosis, investigations, previous drug therapies tried, reasons for drug therapy failure, rationale for continuing vedolizumab throughout pregnancy, number of doses of vedolizumab received pre- and post-conception, disease severity throughout pregnancy, mode of delivery of baby and health of baby post-delivery. Information on the health of babies post-delivery and at time of writing was gathered by telephone conversation with both mothers. Results: In the two patients reported, vedolizumab use in the first and second trimester did not seem to negatively affect the outcome for both mother and baby. Both mothers had well-controlled IBD throughout pregnancy and delivered safely a healthy baby by elective caesarean section at term. At 8 and 4 months, both babies were noted to be healthy, with no congenital abnormality. Conclusions: In these two case reports, vedolizumab was safe and effective in both patient and baby. However, the use of vedolizumab in pregnancy requires further study.
LINKED CONTENTThis article is linked to Jensen et al and Jensen & Barkun papers. To view these articles, https://doi.org/10.1111/apt.16483 and https://doi.org/10.1111/apt.16545
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.